Disclosed is a respirable / inhalable dry powder comprising respirable dry particles that comprise a) magnesium lactate wherein the magnesium lactate provides divalent metal cation in an amount between 0.1% and 2.9% by weight of the dry particle, and b) a pharmaceutical agent such as albuterol, ciprofloxacin, levofloxacin, tobramycin or tiotropium bromide wherein the respirable dry particles have a volume median geometric diameter (VMGD) of 5 microns or less and wherein the composition is preferably for the treatment of a respiratory diseases such as asthma, airway hyperresponsiveness, seasonal allergy, bronchiectasis, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or cystic fibrosis.
